View Older Stories View More Recent Stories

Dec 12, 2019 01:00AM European Commission Approves EVENITY® (romosozumab) For The Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture
Dec 9, 2019 07:45PM UCB Presents Final Results from Phase II Study of Rozanolixizumab in Primary Immune Thrombocytopenia (ITP) at 2019 ASH Annual Meeting
Dec 6, 2019 07:00AM Bimekizumab Phase 3 Psoriasis Study Demonstrates Superiority Versus Humira®
Dec 5, 2019 07:00AM UCB Presents New Data Demonstrating Commitment to Epilepsy at 2019 American Epilepsy Society Meeting
Nov 25, 2019 07:00AM UCB Announces availability of NAYZILAM® (midazolam) Nasal Spray CIV, the first and only nasal rescue treatment for seizure clusters in the U.S.
Nov 15, 2019 07:00AM Bimekizumab Positive Results Confirmed in Second Phase 3 Psoriasis Study
Nov 8, 2019 09:10AM UCB Presents New Data From Rheumatology Portfolio Addressing Unmet Needs in Axial Spondyloarthritis, Psoriatic Arthritis and Lupus at 2019 ACR/ARP
Oct 18, 2019 01:00AM EVENITY® (Romosozumab) Receives Positive CHMP Opinion For The Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture
Oct 17, 2019 07:00AM Bimekizumab Phase 3 Psoriasis Study Meets All Endpoints, Achieving Significantly Greater Efficacy Versus Placebo and Ustekinumab
Oct 10, 2019 07:00AM UCB Agrees to Acquire Ra Pharmaceuticals: Joining Forces to Improve Treatment Options for People Living With Myasthenia Gravis and Other Rare Diseases
Oct 10, 2019 01:22AM UCB Agrees to Acquire Ra Pharmaceuticals: Joining Forces to Improve Treatment Options for People Living With Myasthenia Gravis and Other Rare Diseases
Aug 15, 2019 03:24PM MyHealthTeams Raises $9.44 Million in Financing Round Led By Strategic Investor UCB
Jul 25, 2019 07:00AM UCB Half Year Report 2019: UCB's Strong Performance Enables Continued Investment Into Future Growth Drivers
Jun 28, 2019 01:00AM Amgen and UCB Provide Regulatory Update on Status of EVENITY™ (romosozumab) in the EU
Jun 14, 2019 07:00AM UCB's Key Pipeline Molecule Bimekizumab Demonstrated Improved Outcomes for Ankylosing Spondylitis Patients
May 28, 2019 08:01AM UCB Initiates Phase 1b US-Based Multicenter Clinical Trial in Parkinson’s Disease Patients with UCB0599, a Compound Arising from the Neuropore-UCB Collaboration
May 20, 2019 07:00AM UCB announces NAYZILAM® (midazolam) nasal spray now approved by FDA to treat intermittent, stereotypic episodes of frequent seizure activity in people living with epilepsy in the U.S.
Apr 9, 2019 03:59PM Amgen (AMGN) Confirms FDA Approves EVENITY For Treatment Of Osteoporosis in Postmenopausal Women
Apr 9, 2019 03:57PM FDA Approves EVENITY™ (romosozumab-aqqg) For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture
Mar 28, 2019 06:30PM CIMZIA® (certolizumab pegol) is Now the First and Only U.S. FDA-Approved Treatment for Non-Radiographic Axial Spondyloarthritis
Mar 11, 2019 07:00AM Arthritis & Rheumatology Publishes the First Randomized Placebo-Controlled Study Over 52 Weeks in Non-Radiographic Axial Spondyloarthritis Showing Positive Results for CIMZIA® (certolizumab pegol
Mar 6, 2019 03:00AM UCB Ventures Appoints Alicia Irurzun-Lafitte as Partner
Mar 2, 2019 07:00AM Bimekizumab Demonstrated Long-Term Maintenance of Complete or Almost Complete Skin Disease Resolution for Psoriasis Patients in BE ABLE 2 Extension Study
Mar 1, 2019 07:15AM New Data Affirms Strength of UCB Immuno-Dermatology Portfolio
Mar 1, 2019 07:08AM New Data Affirms Strength of UCB Immuno-Dermatology Portfolio
Feb 28, 2019 01:55PM UCB Full Year Report 2018: 2018 Marks the Fifth Consecutive Year of Profitable Growth, Intensifying Investment in UCB's Strong Pipeline
Jan 16, 2019 05:44PM Amgen (AMGN), UCB Confirm Positive Vote From FDA Panel in Favor of Approval for EVENITY (romosozumab)
Jan 16, 2019 05:41PM Amgen And UCB Receive Positive Vote From FDA Advisory Committee In Favor Of Approval For EVENITY™ (romosozumab)
Jan 8, 2019 04:01PM Amgen (AMGN), ECB Announce EVENITY Received Approval In Japan For Treatment of Osteoporosis
Jan 8, 2019 04:00PM EVENITY™ (romosozumab) Receives Approval In Japan For The Treatment Of Osteoporosis In Patients At High Risk Of Fracture
Nov 30, 2018 04:00PM Amgen (AMGN), UCB Announce FDA Advisory Committee Meeting To Review EVENITY
Nov 30, 2018 04:00PM Amgen And UCB Announce FDA Advisory Committee Meeting To Review EVENITY™ (romosozumab) For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture
Nov 30, 2018 08:00AM UCB presents latest research at 2018 American Epilepsy Society Annual Meeting demonstrating neurology commitment and leadership
Oct 30, 2018 05:00AM UCB First Nine Months Interim Report 2018: UCB tracking well towards full year financial outlook
Oct 23, 2018 05:00PM Bimekizumab Showed Sustained Improvements in Both Joint and Skin Outcomes for Psoriatic Arthritis Patients
Oct 23, 2018 01:00AM UCB and Biogen Announce Topline Results from a Phase 2b Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus
Oct 19, 2018 07:00AM UCB Presents New Long-Term Data Showing Substantial Impact for CIMZIA® (Certolizumab Pegol) in Axial Spondyloarthritis and Rheumatoid Arthritis and Late-Breaking Bimekizumab Data in Psoriatic Arthrit
Oct 18, 2018 07:00AM UCB Accelerates Anti-FcRn Rozanolixizumab in Myasthenia Gravis Into Confirmatory Development Phase
Oct 18, 2018 12:01AM The Impact of Fragility Fractures due to Osteoporosis is Being Ignored
Sep 25, 2018 12:00AM Ceribell Announces Completion Of $35 Million Series B Financing
Aug 13, 2018 08:00AM FDA Accepts New Drug Application (NDA) to review Midazolam Nasal Spray, an investigational product for the acute treatment of seizure clusters
Aug 8, 2018 10:59AM Spondyloarthritis Resource Center Provides Information And Tips For Dealing With Chronic Back And Joint Pain
Jul 13, 2018 05:54AM Amgen (AMGN), UCB Announce Re-submission of Biologics License Application (BLA) For EVENITY (romosozumab) to FDA
Jul 13, 2018 01:00AM Amgen And UCB Resubmit Biologics License Application (BLA) For EVENITY™ (romosozumab) To The US FDA
Jul 11, 2018 08:00AM UCB Launches the Autoimmune Motherhood (AIM) Movement™ to Empower and Inform Women with Chronic Inflammatory Disease About Family Planning
Jul 2, 2018 12:30PM UCB Announces Approval of NEUPRO® in China to Treat Parkinson's Disease
Jun 15, 2018 01:00AM New Study Presented at the Annual European Congress of Rheumatology (EULAR 2018) Reveals Insights About Women with Chronic Rheumatic Diseases During Their Pregnancy Journey
May 29, 2018 08:00AM UCB Announces the Approval of CIMZIA® (certolizumab pegol) for Moderate-to-Severe Plaque Psoriasis, Representing an Important New Option for Patients in the U.S.
May 16, 2018 04:02PM CIMZIA® (certolizumab pegol) is the First Therapy to Demonstrate Positive Results in a 52-week, Placebo Controlled Non-Radiographic Axial Spondyloarthritis Study
May 14, 2018 08:00AM UCB Announces BRIVIACT® (Brivaracetam) now Approved by FDA to Treat Partial-onset (Focal) Seizures in Pediatric Epilepsy Patients
View More Recent Stories View Older Stories